Ticagrelor for acute coronary syndromes
PHARMAC is pleased to announce the approval of an agreement to fund ticagrelor (Brilinta) from 1 July 2013.
May 2013 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and the 2011/12 Invitation to Tender, dated 01 November 2011. *CORRECTED*
Approval of proposal involving pegfilgrastim and tocilizumab
PHARMAC is pleased to announce the approval of a proposal to list pegfilgrastim (Neulastim) for prevention of neutropenia in patients undergoing cancer chemotherapy and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis, from 1 July 2013.
Proposal to fund blood glucose and blood ketone testing products via a PSO
PHARMAC is seeking feedback on a proposal to fund blood glucose and blood ketone testing products via a PSO from 1 July 2013. Closed: Monday, 10 June 2013.
RFI - Compression bandages and hosiery for the treatment of venous leg ulcers
PHARMAC is interested in receiving information from suppliers, DHBs, service providers and treating clinicians on the use and supply of compression bandages for the treatment of venous leg ulcers, compression hosiery for the treatment of venous leg ulcers, compression hosiery butlers, and compression hosiery top bands. Closes: Friday, 5 July 2013.
Hospital use of sugammadex, methoxyflurane, COX-2 inhibitors and gabapentin
PHARMAC is pleased to announce the approval of proposals relating to the hospital use of sugammadex, methoxyflurane, COX-2 inhibitors and gabapentin.
Proposal to decline a funding application for eculizumab
PHARMAC is seeking feedback on a proposal to decline the application from Alexion Pharmaceuticals for funding eculizumab (Soliris) for the treatment of paroxysmal nocturnal haemoglobinuria. Closed: Wednesday, 31 July 2013.
Section H rules and NPPA policy changes
Decisions regarding Schedule rules and policies in relation to hospital medicines funding.
Hospital medicines notification
PHARMAC has announced further decisions related to the funding of hospital medicines.
Decision criteria consultation
PHARMAC is seeking views on the criteria it uses to make its decisions. Closed: Friday, 30 August.
Request for feedback on PHARMAC’s initial medical device activity
PHARMAC is seeking feedback on its initial medical device activity. Closed: Friday, 14 June 2013.
Adalimumab for juvenile idiopathic arthritis and for fistulising Crohn’s disease
PHARMAC has approved a proposal to widen access to adalimumab (Humira and HumiraPen) to include juvenile idiopathic arthritis and fistulising Crohns disease, and to list a 20 mg strength of Humira, from 1 July 2013, through an agreement with AbbVie Limited.
Listing of malathion with permethrin and piperonyl butoxide (Para Plus)
PHARMAC will list malathion with permethrin and piperonyl butoxide (Para Plus) from 6 May 2013.
Proposed access widening for ursodeoxycholic acid
PHARMAC is seeking feedback on a proposal to widen access to ursodeoxycholic acid and amend the criteria for its funded use. Closed: Friday, 17 May 2013.
April 2013 tender notification
PHARMAC has announced that it has awarded tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and the 2010/11 Invitation to Tender, dated 02 November 2010.
RFP - Supply of pegylated interferon, pegylated interferon with ribavirin, boceprevir and telaprevir
PHARMAC invites proposals for the supply of pegylated interferon, pegylated interferon with ribavirin, boceprevir and telaprevir in New Zealand. Closed.
RFP - Influenza vaccine
PHARMAC invites proposals for the supply of seasonal influenza vaccine in New Zealand. Closed.
Decisions relating to hospital medicines funding
PHARMAC has announced further decisions related to the establishment of a nationally consistent list of hospital medicines.
Proposal involving hospital use of sugammadex (Bridion)
PHARMAC is seeking feedback on a proposal to list sugammadex (Bridion) in Part II of Section H of the Pharmaceutical Schedule. Closed: Friday, 3 May 2013.
Proposal involving hospital use of methoxyflurane, COX-2 inhibitors and gabapentin
PHARMAC seeks feedback on listing the following for use in hospitals: methoxyflurane for use in painful procedures; etoricoxib and celecoxib for perioperative use; and to widen access to meloxicam to include perioperative use, and gabapentin to include preoperative use. Closed: Friday, 3 May 2013.
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Te Whaioranga ePānui: A PHARMAC newsletter for people with an interest in Māori health.
